Questions:

1. Who are the “key” stakeholders in this matter, and what are their “stakes”? (1-2 Pages)

- VPC
    - Profits gained and future of company
- Trial patients
    - Their health / not being dead
- Canadian Government
    - Taxes gained
    - Upholding the law
    - Growth of Canadian industries/companies
- Health Canada
    - Public safety
    - pmprb
- Japanese Government
    - Taxes gained
    - Upholding the law
    - Growth of japanese industries/companies
- Public
    - Safety
    - Want a GOOD drug to be in the market, not just a drug that works.
- Angian-san
    - Profits gained and future of company

2. In your view, is the government correct in its position on this issue? Justify your Response. (1 page)

- Government is correct in this decision
- Regulation of the safety of the drug industry.
- People over profits
- Corporate social responsibility
- Does a foreign drug have to undergo canadian testing
- Relevant laws
- Is there a precedence in this case?

3. How does this case demonstrate arguments for and against government regulation of Business? (1 page)

- For
    - "The government argued that this would not be prudent since the cause and effect relationship had not been scientifically established and that the effect of using the plaque reducing medication with the Compound Y was unknown."
        - This shows that government regulation is a positive thing by showing the government's ability to protect its citizens against unsafe products entering the market
        - This drug is an example of a drug that is mostly safe, had the government not regulated business, people in civil society would have access to drugs that could be highly dangerous.

    - Health Canada officials were adamant that the full phased clinical trials be completed before the new drug submission review would occur. This, they said, was the procedure and in the public's interest.
        -
    -

- Against
    - VPC argued that according to the government's own literature, regulation "is intended to promote a fair and competitive market economy"
    - Slows down innovation due to the bureaucracy of trials.
        - Denial to skip phase 3 despite drug outlook

4. Suppose VPC decided to lobby the federal government on this matter. In your view, what would be the best approach? (1 page)

"Venn raised the matter with the federal government, arguing that its clinical trials should not only be allowed to proceed but the government should also waive phase 3 of the clinical trial process, as originally requested by Venn."

- Health Canada
    - That a special case be made for VPC
    - Modification of legislation
    -
-